Diltiazem

Limits on what this shows

• Key negative / null findings: No study identified reports diltiazem impairing mitochondrial function, reducing ATP output, or producing a mitochondrial burden in the sense a consumer nutrient-depletion chart would use the term; the consistent direction across every Tier B source found is protective.
• At-risk subgroups: None identified for a nutrient-mediated effect. Diltiazem's separate, rare, labeled hepatotoxicity is a direct idiosyncratic hepatic reaction, not a nutrient-mediated mitochondrial depletion, and standard drug-induced liver injury monitoring, not nutrient supplementation, is the relevant response if it occurs.

Regulatory status

Not addressed in the FDA label as a nutrient-related finding. StatPearls lists hepatotoxicity among diltiazem's severe adverse effects alongside congestive heart failure and myocardial infarction, but as a clinical outcome of the drug's own toxicity profile, not a nutrient-mediated mitochondrial finding, and no study identified here links that hepatotoxicity to depletion of any specific mitochondrial-support nutrient such as CoQ10, L-carnitine, or B-vitamins.

Population evidence

No Tier A human study measuring a mitochondrial-function biomarker in diltiazem-treated patients was located. All identified evidence is Tier B, animal or in vitro. Diltiazem inhibits the mitochondrial Na+/Ca2+ exchange system in cardiac and brain mitochondria in a stereospecific manner (the d-cis isomer). In a rat left-anterior-descending coronary artery ischemia/reperfusion model (1 mg/kg IV) combined with an H9C2 cardiomyoblast oxygen-glucose-deprivation/recovery model (10^-6 M for 12 hours), diltiazem upregulated DUSP1, downregulated JNK and BNIP3L/NIX, reduced excessive mitophagy markers (lower Beclin1 and LC3B), increased cell viability, and reduced apoptosis and tissue necrosis compared with untreated ischemia/reperfusion controls. In a separate rat model of acute liver injury, diltiazem reduced injury markers via the NFκB-TXNIP/NLRP3 axis, a hepatoprotective rather than hepatotoxic direction, though the full text of that study was blocked on every attempt and no specific magnitude is asserted from it here.

Mechanism

Named and consistent across every identified source: diltiazem's L-type calcium channel blockade limits mitochondrial calcium overload during ischemic or oxidative stress, the same electrophysiological mechanism responsible for its clinical antianginal and antiarrhythmic effects. This is diltiazem's own known pharmacological mechanism of action, not a nutrient-deficiency-driven mitochondrial effect.

Counter-evidence held on record

Every mechanistic study located points toward mitochondrial preservation, not injury, under calcium-overload or ischemic conditions; no drug-specific human mitochondrial biomarker study exists in either direction. Do not present this entry as either a mitochondrial health benefit or a mitochondrial nutrient depletion risk. It documents that diltiazem's calcium-channel-blocking mechanism of action affects mitochondrial calcium handling as part of its known pharmacology, not as a novel nutrient-status finding, and no monitoring or supplementation recommendation should be attached to it.

Limits on what this shows

• Key negative / null findings: No human study measuring a validated oxidative stress biomarker (for example, malondialdehyde, F2-isoprostanes, or total antioxidant capacity) in diltiazem-treated patients versus controls was located in this review.
• At-risk subgroups: None identified.

Regulatory status

Not addressed in the FDA label.

Population evidence

All identified evidence is Tier B. "Diltiazem Attenuates Oxidative Stress in Diabetic Rats" ( Renal Failure, 2005) is named and real, but full text was blocked on every attempt, so no dose, duration, or effect size is asserted from it here beyond its title and protective direction. A direct in vitro comparison found diltiazem showed antioxidant activity against sarcolemmal membrane lipid peroxidation alongside propranolol, nifedipine, and verapamil ( Circulation Research, 1990); full text was blocked, so the comparative ranking among the four drugs is not asserted here. In human umbilical vein endothelial cells, diltiazem inhibited angiotensin-II-induced oxidative stress signaling; this is an in vitro human cell line study, not a clinical human study, and full text was blocked. One narrower animal source carries a title suggesting d-cis-diltiazem can produce oxidative stress in depolarized retinal rods in a mouse model; the accessible portion of that source described only the calcium-channel-blocking pharmacology behind the experiment, not the oxidative-stress outcome itself, so the specific pro-oxidant claim in its title could not be independently confirmed here.

Mechanism

Where proposed, the mechanism is the same L-type calcium channel blockade discussed in the mitochondrial entry above: less calcium influx during stress is proposed to mean less calcium-triggered reactive oxygen species generation. This is protective-direction pharmacology, not a nutrient-consuming mechanism, and does not implicate any specific antioxidant nutrient (vitamin C, vitamin E, glutathione, selenium) as being depleted.

Counter-evidence held on record

Three of four identified mechanistic sources point toward an antioxidant, protective direction; the fourth's specific pro-oxidant claim could not be verified past its title. No consistent depletion-direction signal exists to support a consumer-facing oxidative stress risk claim. Do not present diltiazem as either protecting against or causing oxidative stress for a general consumer audience. The evidence is Tier B, animal and in vitro only, the direction is not consistently one way, and no antioxidant nutrient has been shown to be depleted by this drug in any study located.

Limits on what this shows

• Key negative / null findings: No study directly measuring iron status in diltiazem-treated patients, positive or negative, was located in this review.
• At-risk subgroups: If a true effect exists and extends to non-dihydropyridines, heart-failure patients with pre-existing iron deficiency would be the plausible at-risk group, mirroring the population actually studied; but diltiazem's own contraindication-adjacent status in heart failure with reduced ejection fraction makes this population unlikely to be co-prescribed diltiazem in the first place.

Regulatory status

Not addressed in the FDA label; no iron-related warning appears anywhere in diltiazem's labeling.

Population evidence

A prospective observational study of 128 heart-failure patients with iron deficiency found significantly lower serum iron (p=0.038), hematocrit (p=0.003), and hemoglobin (p=0.018) in patients using a calcium channel blocker versus those not using one. The authors state explicitly that every CCB-treated patient in their cohort was using amlodipine, and note in their introduction that diltiazem and verapamil "are not recommended in heart failure with reduced ejection fraction," meaning diltiazem was not represented in the studied population at all. This is Tier C for diltiazem: real Tier A human data exists for a class member, not for diltiazem itself, and the two CCB subclasses (dihydropyridine versus non-dihydropyridine) differ in tissue selectivity and binding site on the L-type calcium channel, which weakens, but does not eliminate, the extrapolation.

Mechanism

The study's authors propose impaired erythropoietin response, reduced intestinal iron absorption via DMT1 transporter inhibition, and possible gastrointestinal bleeding risk as candidate mechanisms. DMT1 is a divalent metal transporter, and L-type calcium channel blockade has a plausible, if unconfirmed, path to affecting it, so this mechanism is not implausible for diltiazem in principle, but it has not been tested for diltiazem specifically.

Counter-evidence held on record

The only human data located names amlodipine, not diltiazem, and diltiazem is described in that same source's own introduction as not recommended in the heart-failure population studied. No diltiazem-specific iron, hemoglobin, or hematocrit data was located in either direction. A reverse-direction consumer interaction report separately suggests iron-containing multivitamins may reduce diltiazem's antihypertensive effect rather than the drug affecting iron status; that reverse-direction concern is not itself evidence of iron depletion and is noted here only for completeness. Do not present this as an established diltiazem-iron-deficiency risk. The supporting study excluded diltiazem from its cohort by the authors' own description; this entry documents a class-extrapolated hypothesis, not a diltiazem-specific finding, and no iron supplementation recommendation should be attached to it.

Limits on what this shows

• Why no grade: Targeted search for diltiazem and copper status, serum copper, ceruloplasmin, or copper-dependent enzyme activity returned no drug-specific results at any evidence tier, and none of the consumer nutrient-depletion sources checked for this dossier (including the Coastal Pharmacy and Wellness chart already cited, which places diltiazem under "No Known Significant Depletions") name copper for diltiazem or its class. The mechanism screen found no plausible pathway: diltiazem does not chelate metals, does not alter gastric pH, is not a diuretic, and its principal transporter interaction (P-glycoprotein inhibition) has no established link to copper handling.
• What would fill it: A study, at minimum Tier B (animal or in vitro), directly measuring a copper-status biomarker, such as serum copper, ceruloplasmin, or a copper-dependent enzyme like superoxide dismutase or cytochrome c oxidase activity, in diltiazem-exposed tissue or subjects.

Counter-evidence held on record

None to hold; there is nothing to rebut and nothing to confirm. The absence of evidence is the finding. Do not convert this gap into a reassurance that diltiazem is "safe for copper status." No one has looked. This entry exists to record that fact plainly, not to imply either risk or safety.

Limits on what this shows

• Key negative / null findings: The absence of any diltiazem-specific host-microbiome composition study is itself the main finding here, not affirmative evidence of no effect.
• At-risk subgroups: None identified. Confounding by indication is the dominant consideration: hypertension and cardiovascular disease are independently associated with gut dysbiosis in the broader literature, so any future finding of altered microbiome composition in diltiazem-treated patients would need to rule out the underlying cardiovascular condition and its associated lifestyle and dietary factors before attributing it to the drug.

Regulatory status

Not addressed in the FDA label.

Population evidence

A structural biology study identified a hydrolase enzyme, BT4096, produced by the gut bacterium Bacteroides thetaiotaomicron, that metabolizes diltiazem by removing an acetyl group to produce diacetyl-diltiazem. This is Tier B, in vitro and structural, and describes the microbiome acting on the drug, affecting its metabolite profile, not the drug acting on the microbiome; the study authors note the enzyme likely evolved for oligosaccharide metabolism and acts on diltiazem incidentally. No study measuring diltiazem's effect on gut microbial composition or diversity (16S rRNA sequencing or equivalent) was located in this review.

Mechanism

No mechanism by which diltiazem would disrupt the host microbiome was identified in the mechanism screen. Diltiazem is not an antibiotic, is not documented to alter gastric pH, and no bile-acid-sequestration or GI-motility adverse effect is listed in diltiazem's own labeling or in the StatPearls adverse-effect summary used for the base dossier, which lists peripheral edema, bradycardia, dizziness, headache, and fatigue as common effects, and congestive heart failure, myocardial infarction, and hepatotoxicity as severe ones; no gastrointestinal-motility effect is named there.

Counter-evidence held on record

The one verified drug-microbiome relationship for diltiazem is bacteria acting on the drug, not the drug acting on bacteria; no composition or diversity data in either direction was located. Do not present this as evidence that diltiazem disrupts gut health. No study measuring the effect of diltiazem on the composition of the human gut microbiome was located in this review; if such an effect exists, it has not yet been demonstrated, and the underlying cardiovascular condition, not the drug, is the more established correlate of gut dysbiosis in the general hypertension literature.

Limits on what this shows

• Key negative / null findings: No study located reports diltiazem reducing ATP output or synthesis in any tissue.
• At-risk subgroups: None identified.

Regulatory status

Not addressed in the FDA label.

Population evidence

An in vitro study of isolated rat heart mitochondria examined diltiazem's effect on calcium accumulation and ATP synthesis together; the title indicates the two processes were measured simultaneously, but the full text was blocked on every attempt and no specific direction or magnitude is asserted from it here beyond its existence. The separately verified ischemia/reperfusion and mitophagy study discussed under Mitochondrial calcium handling above, diltiazem preserving mitochondrial function and reducing excessive mitophagy in rat heart tissue and H9C2 cells, bears directly on ATP-generating capacity, since preserved mitochondrial structure is a precondition for preserved ATP output, but that finding is counted once, under the mitochondrial entry, per the overlap map below.

Mechanism

Same as the mitochondrial calcium handling entry: L-type calcium channel blockade limiting mitochondrial calcium overload is diltiazem's documented mechanism of action, plausible for preserving rather than degrading ATP synthesis capacity under ischemic stress. This is not a nutrient-deficiency mechanism.

Counter-evidence held on record

This entry rests on the same evidence base as Mitochondrial calcium handling above; see the overlap map below for how the two are kept from double-counting one signal as two independent findings. Do not present this as either an energy-boosting benefit or an ATP-depletion risk. No nutrient, CoQ10, creatine, B-vitamins, or otherwise, is implicated in any identified study, and the underlying evidence is animal and in vitro only.

Limits on what this shows

• Why no grade: A human-titled source, "Improved myocardial oxygen utilization by diltiazem in patients," was identified, but its full text was blocked on every attempt, so no sample size or magnitude is asserted from it here. By title, and by established calcium-channel-blocker pharmacology, this line of evidence describes diltiazem's negative inotropic and chronotropic effects and coronary vasodilation reducing myocardial oxygen demand, the established basis for its use in angina. This is a demonstrated clinical effect of the drug itself, not a nutrient-mediated finding, and per the rule against filing a drug's own known pharmacological action as a nutrient deficiency, it is not graded here as one. The hemoglobin and hematocrit signal relevant to oxygen-carrying capacity is addressed once, under the Iron entry above, and is not re-counted here. No study was located showing diltiazem impairs tissue oxygen delivery or utilization through any nutrient-dependent pathway, iron, B12, or otherwise.
• What would fill it: A study measuring a validated tissue-oxygenation or oxygen-utilization biomarker in diltiazem-treated patients that is attributable to a nutrient mechanism rather than to diltiazem's own hemodynamic action, with a comparison group.

Counter-evidence held on record

The only evidence found by title (improved myocardial oxygen utilization) runs in the beneficial direction and reflects known pharmacology, not a deficiency. Do not present this as either a nutrient-related oxygen-delivery risk or a nutrient-related benefit. Diltiazem's effect on myocardial oxygen demand is a demonstrated clinical action of the drug itself and must not be relabeled as a nutrient-status finding in either direction.